Constellation Pharmaceuticals
Clinical trials sponsored by Constellation Pharmaceuticals, explained in plain language.
A biopharmaceutical company developing cancer therapies targeting epigenetic regulators.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
-
New drug combo shrinks spleens in bone marrow cancer patients
Disease control CompletedThis study tested a new drug called pelabresib in people with certain blood cancers, including myelofibrosis and leukemia. In the first part, the drug was given alone to find the safest dose. In the second part, it was given with or without another drug (ruxolitinib) to see if it…
Phase 1/2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Experimental combo aims to outsmart resistant prostate cancer
Disease control CompletedThis study tested an experimental drug called CPI-1205 combined with standard hormone therapies (enzalutamide or abiraterone/prednisone) in 175 men with metastatic castration-resistant prostate cancer, a form of prostate cancer that has spread and stopped responding to usual horm…
Phase 1/2 • Sponsor: Constellation Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:55 UTC